848 related articles for article (PubMed ID: 20666396)
1. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
[TBL] [Abstract][Full Text] [Related]
2. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
[TBL] [Abstract][Full Text] [Related]
4. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
Veal GJ; Dias C; Price L; Parry A; Errington J; Hale J; Pearson AD; Boddy AV; Newell DR; Tilby MJ
Clin Cancer Res; 2001 Aug; 7(8):2205-12. PubMed ID: 11489793
[TBL] [Abstract][Full Text] [Related]
5. Novel binding interactions of the DNA fragment d(pGpG) cross-linked by the antitumor active compound tetrakis(mu-carboxylato)dirhodium(II,II).
Chifotides HT; Koshlap KM; Pérez LM; Dunbar KR
J Am Chem Soc; 2003 Sep; 125(35):10714-24. PubMed ID: 12940757
[TBL] [Abstract][Full Text] [Related]
6. Polymerization by DNA polymerase eta is blocked by cis-diamminedichloroplatinum(II) 1,3-d(GpTpG) cross-link: implications for cytotoxic effects in nucleotide excision repair-negative tumor cells.
Chijiwa S; Masutani C; Hanaoka F; Iwai S; Kuraoka I
Carcinogenesis; 2010 Mar; 31(3):388-93. PubMed ID: 20015866
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
8. Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA.
Meczes EL; Azim-Araghi A; Ottley CJ; Pearson DG; Tilby MJ
Biochem Pharmacol; 2005 Dec; 70(12):1717-25. PubMed ID: 16259963
[TBL] [Abstract][Full Text] [Related]
9. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
Kasparkova J; Novakova O; Farrell N; Brabec V
Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
[TBL] [Abstract][Full Text] [Related]
10. One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes.
Yamada K; Kato N; Takagi A; Koi M; Hemmi H
Anal Bioanal Chem; 2005 Aug; 382(7):1702-7. PubMed ID: 15959768
[TBL] [Abstract][Full Text] [Related]
11. Quantitative correlation of drug bioactivation and deoxyadenosine alkylation by acylfulvene.
Neels JF; Gong J; Yu X; Sturla SJ
Chem Res Toxicol; 2007 Oct; 20(10):1513-9. PubMed ID: 17900171
[TBL] [Abstract][Full Text] [Related]
12. Determination of platinum in human subcellular microsamples by inductively coupled plasma mass spectrometry.
Björn E; Nygren Y; Nguyen TT; Ericson C; Nöjd M; Naredi P
Anal Biochem; 2007 Apr; 363(1):135-42. PubMed ID: 17286953
[TBL] [Abstract][Full Text] [Related]
13. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma.
Fichtinger-Schepman AM; Vendrik CP; van Dijk-Knijnenburg WC; de Jong WH; van der Minnen AC; Claessen AM; van der Velde-Visser SD; de Groot G; Wubs KL; Steerenberg PA
Cancer Res; 1989 Jun; 49(11):2862-7. PubMed ID: 2720647
[TBL] [Abstract][Full Text] [Related]
14. Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro.
Kostrhunova H; Vrana O; Suchankova T; Gibson D; Kasparkova J; Brabec V
Chem Res Toxicol; 2010 Nov; 23(11):1833-42. PubMed ID: 20939593
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
Pluim D; van Waardenburg RC; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):71-8. PubMed ID: 15034754
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.
Welters MJ; Fichtinger-Schepman AM; Baan RA; Jacobs-Bergmans AJ; Kegel A; van der Vijgh WJ; Braakhuis BJ
Br J Cancer; 1999 Jan; 79(1):82-8. PubMed ID: 10408697
[TBL] [Abstract][Full Text] [Related]
17. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S
Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376
[TBL] [Abstract][Full Text] [Related]
18. Marked dependence on carrier-ligand bulk but not on carrier-ligand chirality of the duplex versus single-strand forms of a DNA oligonucleotide with a series of G-Pt(II)-G intrastrand cross-links modeling cisplatin-DNA adducts.
Beljanski V; Villanueva JM; Doetsch PW; Natile G; Marzilli LG
J Am Chem Soc; 2005 Nov; 127(45):15833-42. PubMed ID: 16277526
[TBL] [Abstract][Full Text] [Related]
19. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin.
Scheeff ED; Briggs JM; Howell SB
Mol Pharmacol; 1999 Sep; 56(3):633-43. PubMed ID: 10462551
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry.
Hah SS; Stivers KM; de Vere White RW; Henderson PT
Chem Res Toxicol; 2006 May; 19(5):622-6. PubMed ID: 16696564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
